Fig. 3From: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort studyRate of subsequent exacerbations following FF/UMEC/VI initiation. FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, CI confidence interval. ≤ 14 days was performed as an additional analysis. p-values in bold text indicate statistical significanceBack to article page